Home/Pipeline/Neurology Diagnostics Program

Neurology Diagnostics Program

Neurological Disorders

DiscoveryActive

Key Facts

Indication

Neurological Disorders

Phase

Discovery

Status

Active

Company

Aptus Biosciences

About Aptus Biosciences

Aptus Biosciences is a private, pre-revenue diagnostics company focused on reinventing aptamer technology for clinical applications. The company is developing a platform of chemically modified DNA aptamers designed as high-specificity, high-affinity reagents for detecting disease biomarkers. Its initial pipeline targets major therapeutic areas including neurology, oncology, cardiology, and infectious diseases, with the goal of enabling earlier and more accurate diagnosis. As an early-stage venture, Aptus is likely seeking partnerships and investment to advance its programs from platform development into validated diagnostic assays.

View full company profile

Therapeutic Areas

Neurology Oncology Cardiology Infectious Diseases

Other Neurological Disorders Drugs

Drug	Company	Phase	Status
Biomarker Development Program	NeuroVision Imaging	Research	Active
GlyT2 Inhibitor Program	Micar Innovation	Discovery	Active
Biomarker Discovery & Validation Services	NeuroDex	Service	Active
Clinical Trial Biomarker Support	NeuroDex	Service	Active
CNS-Targeting Capsids	rAAVen Therapeutics	Pre-clinical	Active
IVL-002	InVirtuoLabs	Discovery	Active
IVL-003	InVirtuoLabs	Discovery	Active
GM1 Ganglioside-based Therapies	TRB Chemedica International	Commercial / Development	Active
Undisclosed Neurology Programs	BridGene Biosciences	Discovery	Active
iPSC Platform Programs	Evotec	Preclinical Research	Active
ExacTcell Platform	Tevogen Bio	Discovery/Preclinical	Research